La sarcoïdose: une nouvelle complication de traitement par l'interféron alpha

Liozon, É.; Cransac, M.; Remenieras, Liliane; Catry-Thomas, I.; Vovor, A.; Bron, Dominique

doi:10.1016/s0248-8663(05)80272-3

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1986, Abdi et al (55) reported the first pathologically proven case of IFN‐induced sarcoidosis in a woman treated with IFN‐β for advanced renal cell carcinoma. Since that time, to date, there has been other 64 published reports (including the current illustrative case) that supports a possible association between IFN therapy and the development or recurrence of sarcoidosis (Table 3) (55–100). Hoffmann et al (66) reported a 5% incidence of sarcoidosis in a cohort of 60 patients who participated in a randomised trial of IFN‐α for CHC infection.…”

Section: Ifn‐induced Sarcoidosis (Iis)mentioning

confidence: 57%

Interferon-induced sarcoidosis

Alazemi

Campos

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

Interferons (IFNs) are widely used for the treatment of various medical diseases. They have marked immunomodulatory effects, and many reports have been published associating IFN therapy with the induction of autoimmune phenomena and other disorders of immune regulation such as sarcoidosis. The clinical presentation of IFN-induced sarcoidosis (IIS) is insidious and can be confused with common constitutional side effects of these drugs. The age of onset of IIS is later than that of naturally occurring sarcoidosis. The most common organs involved are the lungs and skin. In the majority of cases, IIS follows a benign course. As we show in an illustrative case report, complete resolution after discontinuation of IFN therapy can be expected. This review summarises 65 cases of IIS reported in the literature and highlights the pathophysiology, clinical features, diagnostic modalities and therapeutic options for this increasingly recognised phenomenon.

show abstract

Section: Ifn‐induced Sarcoidosis (Iis)mentioning

confidence: 57%

Interferon-induced sarcoidosis

Alazemi

Campos

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…published the first case of pulmonary sarcoidosis following interferon therapy for renal carcinoma 1 . Since that date, there have been more than 20 observations of the occurrence or exacerbation of this granulomatosis with interferon 2–22 . In 24 cases interferon alfa was administered alone (12 hepatitis, eight chronic myelogenous leukaemia, two cutaneous lymphoma, one HBV, one renal cancer), in three cases interferon alfa was given with ribavirin for chronic HCV, 2,22 and in two cases cutaneous and pulmonary sarcoidosis occurred with interferon beta 8,14 .…”

Section: Discussionmentioning

confidence: 99%

Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases

Cogrel¹,

Doutre²,

Marlière³

et al. 2002

Br J Dermatol

View full text Add to dashboard Cite

Interferon-induced sarcoidosis is well documented. We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin. These patients developed cutaneous sarcoidosis about 3 months after the beginning of the combination therapy. Spontaneous regression of the lesions was noted after discontinuation of the treatment. There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin. Dermatological signs are found in 50% of cases, and are often diagnostic. Other clinical symptoms of sarcoidosis resemble side-effects of interferon. The evolution is fairly stereotypical and is marked by a regression of the lesions following a dose reduction or curtailment of interferon. Interferon alfa acts by stimulating the T-helper (Th) 1 immune response. In addition to its antiviral action, ribavirin also enhances the Th1 response. Indeed, the superiority of the combination of interferon alfa and ribavirin in terms of antiviral action is corroborated by the enhancement of a Th1-type immune reaction by this combination. At the same time, this immune cell reaction triggers a greater granulomatous reaction.

show abstract

“…IFN-induced sarcoidosis has also been reported by a French group. Liozon et al 6 treated a patient for CML with high-dose daily IFN (8 MU). After 12 months of IFN therapy, skin nodules developed.…”

Section: Literature Reviewmentioning

confidence: 99%

“…2 There have been scattered case reports of IFN-induced sarcoidosis and/or exacerbation of quiescent sarcoidosis that have "necessitated" the termination of IFN treatment. [3][4][5][6] Because many of the symptoms of sarcoidosis cytes, and eosinophils. Special stains for fungus and tuberculosis, using periodic acid Schiff (PAS) and acidfast bacillus (AFB) were negative.…”

Section: Introductionmentioning

confidence: 99%

Reactivation of sarcoidosis during interferon therapy

Yong

Srinivas

et al. 2002

J Gastroenterol

View full text Add to dashboard Cite

The exacerbation of a co-existing autoimmune disease is often a concern for physicians who use immunomodulating agents for the treatment of a concomitant process. As physicians begin to treat chronic hepatitis C more often and more aggressively, this potential problem with occur more frequently. Herein we reported a case of reactivation of sarcoidosis occurring during the treatment of chronic hepatitis C, and we present a literature review of other centers' experiences with this problem. Depending upon the severity of the exacerbation and the type of organ involvement, reactivation of sarcoidosis may require discontinuation of the interferon therapy, with or without the use of additional steroids. The majority of patients, however, do not require the use of steroids. Interestingly, continuation of the interferon therapy in the presence of a mild-to-moderate exacerbation of sarcoidosis may be safe in a minority of patients with noncritical organ involvement.

show abstract

La sarcoïdose: une nouvelle complication de traitement par l'interféron alpha

Cited by 7 publications

References 0 publications

Interferon-induced sarcoidosis

Interferon-induced sarcoidosis

Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases

Reactivation of sarcoidosis during interferon therapy

Contact Info

Product

Resources

About